Swati Dabral

Wuerzburg, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Pathophysiological and therapeutic implications of C-type natriuretic peptide/cyclic GMP signaling in pulmonary fibrosis.

Pathophysiological and therapeutic implications of C-type natriuretic peptide/cyclic GMP signaling in pulmonary fibrosis.

Journal: JCI insight
Published: January 07, 2026

Pathophysiological and therapeutic implications of C-type natriuretic peptide/cyclic GMP signaling in pulmonary fibrosis.

Pathophysiological and therapeutic implications of C-type natriuretic peptide/cyclic GMP signaling in pulmonary fibrosis.

Journal: JCI insight
Published: June 16, 2025

C-type natriuretic peptide attenuates enhanced glycolysis and de novo pyrimidine synthesis in pericytes of patients with pulmonary arterial hypertension.

C-type natriuretic peptide attenuates enhanced glycolysis and de novo pyrimidine synthesis in pericytes of patients with pulmonary arterial hypertension.

Journal: Communications biology
Published: December 16, 2024

C-type natriuretic peptide/cGMP/FoxO3 signaling attenuates hyperproliferation of pericytes from patients with pulmonary arterial hypertension.

C-type natriuretic peptide/cGMP/FoxO3 signaling attenuates hyperproliferation of pericytes from patients with pulmonary arterial hypertension.

Journal: Communications biology
Published: July 27, 2023

Targeting Wnt-ß-Catenin-FOSL Signaling Ameliorates Right Ventricular Remodeling.

Targeting Wnt-ß-Catenin-FOSL Signaling Ameliorates Right Ventricular Remodeling.

Journal: Circulation research
Published: April 12, 2023

Noncanonical HIPPO/MST Signaling via BUB3 and FOXO Drives Pulmonary Vascular Cell Growth and Survival.

Noncanonical HIPPO/MST Signaling via BUB3 and FOXO Drives Pulmonary Vascular Cell Growth and Survival.

Journal: Circulation research
Published: February 07, 2022

C-type natriuretic peptide moderates titin-based cardiomyocyte stiffness.

C-type natriuretic peptide moderates titin-based cardiomyocyte stiffness.

Journal: JCI insight
Published: May 04, 2020

Maternal and perinatal obesity induce bronchial obstruction and pulmonary hypertension via IL-6-FoxO1-axis in later life.

Maternal and perinatal obesity induce bronchial obstruction and pulmonary hypertension via IL-6-FoxO1-axis in later life.

Journal: Nature communications
Published: April 03, 2020

Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension.

Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension.

Journal: Scientific reports
Published: January 18, 2020

3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung.

3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung.

Journal: Circulation. Cardiovascular imaging
Published: October 26, 2018

A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension.

A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension.

Journal: Nature communications
Published: July 02, 2018

FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis.

FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis.

Journal: EMBO molecular medicine
Published: December 09, 2017
Showing 1-12 of 16

Last Updated: 09/26/2026